Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

Publication

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

Journal Paper/Review - Nov 3, 2008

Viale Giuseppe, Olszewski Wojciech P, Knox Fiona, Thürlimann Beat, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Gusterson Barry A, Goldhirsch Aron, Orosz Zsolt, Neven Patrick, Öhlschlegel Christian, Giobbie-Hurder Anita, Regan Meredith M, Coates Alan S, Mastropasqua Mauro G, Dell'Orto Patrizia, Maiorano Eugenio, MacGrogan Gaëtan, Braye Stephen G, Breast International Group Trial 1-98

Citation

Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.

Type

Journal Paper/Review (English)

Journal

J Clin Oncol 2008; 26

Publication Date

Nov 3, 2008

Issn Electronic

1527-7755

Pages

5569-75

Brief description/objective

To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer.